PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
Siemens Healthineers showcases its AI-powered technological innovations to redefine healthcare delivery in Southeast Asia
Spotlights how scaling AI and big data can make clinical pathways more efficient Hosts its second ASEAN CEO Summit to drive collaboration amongst healthcare leaders to redefine care delivery in Southeast ...
2026-09-01T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals   Trade show news 
Singapore is the first ASEAN country to provide government subsidy for eligible patients receiving vutrisiran for transthyretin amyloidosis
"From September 2026 – eligible patients receiving vutrisiran will receive government subsidies of up to 75% [1] , [2] " ...
2026-09-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Company to host a corporate update call Tuesday, September 1st at 8:00am ET ...
2026-09-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Convergen Secures $15 Million Seed+ Financing to Advance Therapeutics for Protein Aggregation Diseases
SUZHOU, China , Aug. 31, 2026 /PRNewswire/ -- Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today ...
2026-08-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
CS2009 Achieved Key Clinical Validations for Efficacy and Safety ...
2026-08-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors
MT027 has previously been granted FDA Orphan Drug Designation and has entered Phase II clinical development in recurrent glioblastoma ...
2026-08-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Fosun International Holds 2026 Interim Results Presentation: Unlocking Core Pathways, Accelerating Growth in Industries where we Excel
HONG KONG , Aug. 31, 2026 /PRNewswire/ -- On the morning of 28 August, Fosun International held its 2026 interim results presentation in Hong Kong. This marks Fosun's return to Hong Kong to ...
2026-08-31T    Health Care/Hospital   Insurance   Medical/Pharmaceuticals 
Samsung Biologics publishes prospectus for PolyPeptide public tender offer
Direct subsidiary Samsung Peptide AG acting as formal offeror of the public tender offer Publication of offer prospectus follows pre-announcement on July 20, 2026 Largest individual shareholder committed ...
2026-08-31T    Biotechnology   Chemical   Health Care/Hospital   Medical/Pharmaceuticals 
Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore
Columvi (glofitamab) will be added to the Cancer Drug List (CDL) and Medication Assistance Fund (MAF) on 1 September 2026 for eligible patients with relapsed or refractory diffuse large B-cell lymphoma ...
2026-08-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion
SHANGHAI , Aug. 31, 2026 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), ...
2026-08-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.